Dnmt1N/+ reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice independently of p53 but demonstrates strong synergy with the modifier of Min 1AKR resistance allele

Cancer Research

Volumn 60, Issue 14, 2000, Pages 3965-3970

  Cormier, R T ^a   Dove, W F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DERIVATIVE; DNA; DNA METHYLTRANSFERASE; PROTEIN P53; BROXURIDINE; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1;

ADENOMA; ANIMAL EXPERIMENT; ARTICLE; CANCER INCIDENCE; CANCER THERAPY; COLON CANCER; COLON CARCINOGENESIS; DNA METHYLATION; GENOME; INTESTINE CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIPPLE SYNDROME; TUMOR GROWTH; TUMOR RESISTANCE; AGE; ALLELE; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL DIVISION; DNA REPLICATION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; GENOTYPE; INTESTINE TUMOR; MALE; METABOLISM; MITOSIS; MOUSE MUTANT; MUTATION; PATHOLOGY; PHYSIOLOGY; SITE DIRECTED MUTAGENESIS; TUMOR SUPPRESSOR GENE;

ADENOMA; AGE FACTORS; ALLELES; ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CELL DIVISION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA REPLICATION; FEMALE; GENES, P53; GENOTYPE; GERM-LINE MUTATION; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MITOSIS; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS, EXPERIMENTAL;

EID: 0034660686     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
2. Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver
3. Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma
4. Hypomethylation of ras oncogenes in primary human cancers
5. Relaxation of insulin-like growth factor 11 gene imprinting implicated in Wilms tumor
6. Mutation and cancer: Statistical study of retinoblastoma
7. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene
8. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
9. INK4b
10. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site
11. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
12. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas
13. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis
14. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia
15. INK4a alleles in neoplasia
16. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
17. Lessons from hereditary colorectal cancer
18. INK4b
19. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
20. Allelic losses and DNA methylation at DNA mismatch repair loci in sporadic colorectal cancer
21. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability
22. Biallelic inactivation of hMLH1 by epigenetic silencing, a novel mechanism causing human MSI cancers
23. Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer
24. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma
25. MUC2 gene suppression in human colorectal carcinomas and their metastases: In vitro evidence of the modulatory role of DNA methylation
26. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
27. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
28. APC mutations occur early during colorectal tumorigenesis
29. Suppression of intestinal neoplasia by DNA hypomethylation
30. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases
31. Mutagenic and epigenetic effects of DNA methylation
32. Cytosine methylation determines hot spots of DNA damage in the human p53 gene
33. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
34. DNA hypomethylation leads to elevated mutation rates
35. DNA methylation in eukaryotic chromosome stability revisited: DNA methyltransferase in the management of DNA conformation space
36. DNA methylation and genetic instability in colorectal cancer cells
37. Experimental manipulation of genomic methylation
38. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
39. Exploring the bowels of DNA methylation
40. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse
41. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors
42. A subset of p53-deficient embryos exhibits exencephaly
43. Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice
44. Rapid allelotype analysis of p53 knockout mice
45. A possible explanation for the differential cancer incidence in the intestine, based on distribution of the cytotoxic effects of carcinogens in the murine large bowel
46. Scoring mitotic activity in longitudinal sections of crypts of the small intestine
47. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis
48. p53, the cellular gatekeeper for growth and division
49. Tumorigenesis in the multiple intestinal neoplasia mouse: Redundancy of negative regulators and specificity of modifiers
50. WAF1
51. WAF/Cip1 by distinct mechanisms
52. 1 checkpoint control
53. 1 arrest in human cancer cells
54. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis
55. Sulindac suppresses tumorigenesis in the Min mouse
56. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
57. Genotype-phenotype correlation in murine Apc mutation: Differences in enterocyte migration and response to sulindac
58. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration
59. h) labeling distribution as a marker for hereditary predisposition to colon cancer
60. APC in the regulation of intestinal crypt fission
61. Regulated demethylation of the MyoD distal enhancer during skeletal myogenesis
62. Induction of myogenic differentiation by an expression vector encoding the DNA methyltransferase cDNA sequence in the antisense orientation
63. Differentiation of two mouse cell lines is associated with hypomethylation of their genomes
64. Cytosine methylation and mammalian development
65. DNA methylation is a reversible biological signal
66. Reduced mRNA expression of the DNA demethylase, MBD2, in human colorectal and stomach cancers
67. N-ethyl-N-nitrosourea treatment of multiple intestinal neoplasia (Min) mice: Age-related effects on the formation of intestinal adenomas, cystic crypts, and epidermoid cysts
68. CpG island methylator phenotype in colorectal cancer
69. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis
70. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression